Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    DSSTox_CID_28975

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 48,134Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Inlyta

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 477

    2018 Revenue in Millions : 298

    Growth (%) : 60

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 787

    2019 Revenue in Millions : 477

    Growth (%) : 65

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,002

    2020 Revenue in Millions : 787

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 1,003

    2021 Revenue in Millions : 1,002

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,036

    2022 Revenue in Millions : 1,003

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 978

    2023 Revenue in Millions : 1,036

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2014 Revenue in Millions : 28.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Inlyta

    Axitinib

    arrow
    IPPE
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    IPPE
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 410

    2014 Revenue in Millions : 430

    Growth (%) : 5%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Inlyta

    Axitinib

    arrow
    Cosmoprof
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    Cosmoprof
    Not Confirmed

    Pfizer

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 401

    2015 Revenue in Millions : 430

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Inlyta

    Axitinib

    arrow
    Cosmoprof
    Not Confirmed

    Brand Name : Inlyta

    U.S.A
    arrow
    Cosmoprof
    Not Confirmed

    Pfizer Inc.

    Axitinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 339

    2016 Revenue in Millions : 401

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.